Nibec Co., Ltd.

9 patents currently held · Updated Nov 14, 2026

1 more in force is now held by another company

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Mar 2029

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

No maintenance fee falls due on this company's record before Nov 14, 2027.

Recent changes

1 of the patents on this record was granted since Aug 16, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 9 of 9

Patent	Title	Status	Expires	Confidence
US 8,349,804	Bone Graft and Scaffolding Materials Immobilized with Type I Collagen Binding Peptides In force Term ends Mar 22, 2029 · High confidence	In force	Term ends Mar 22, 2029	High confidence
US 10,821,065	Peptide for Inhibiting Biofilms In force Term ends Mar 19, 2038 · High confidence	In force	Term ends Mar 19, 2038	High confidence
US 12,486,303	Novel Use of Peptide for Inhibiting Functions and Expressions of Multiple Disease Biomarkers In force Term ends Mar 10, 2039 · Medium confidence	In force	Term ends Mar 10, 2039	Medium confidence
US 11,384,120	Peptide capable of binding to biomarker for inflammatory and metabolic diseases, and use thereof In force Term ends Aug 29, 2039 · From the USPTO record	In force	Term ends Aug 29, 2039	From the USPTO record
US 12,161,518	Composition for treating and preventing gingivoperiodontitis or peri-implantitis, and interdental brush coated with same In force Term ends Apr 12, 2041 · From the USPTO record	In force	Term ends Apr 12, 2041	From the USPTO record
US 12,655,413	Fragmented GRS Polypeptide and Variant Thereof, and Use Thereof In force Term ends Sep 1, 2042 · High confidence	In force	Term ends Sep 1, 2042	High confidence
US 12,545,704	Peptide for Treating Inflammation and Wounds In force Term ends May 19, 2043 · High confidence	In force	Term ends May 19, 2043	High confidence
US 12,698,313	Bone Morphogenetic PROTEIN-9 and -10 Variants with Enhanced Therapeutic Effect Due to Reduced Side Effects of Ectopic Ossification and Pharmaceutical Composition Comprising Same In force Term ends Jun 22, 2043 · High confidence	In force	Term ends Jun 22, 2043	High confidence
US 12,780,940	Protein Comprising Antibody for Targeting Oncogenic Protein or Single Chain Fragment Variable Thereof and Cancer Cell Penetrating Peptide, and Use of the Same In force Term ends Oct 19, 2043 · High confidence	In force	Term ends Oct 19, 2043	High confidence

Also on record, not counted in the 9: 1 patent in force now held by others. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

8 pending · 2 abandoned

List them